Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Quentin Jacquinot"'
Autor:
Chloé Drozd, Elsa Curtit, Quentin Jacquinot, Charlène Marquine, Laura Mansi, Loïc Chaigneau, Erion Dobi, Julien Viot, Guillaume Meynard, Marie-Justine Paillard, Morgan Goujon, Pauline Roux, Dewi Vernerey, Valérie Gillet, Hubert Bourdin, Silvio Galli, Nathalie Meneveau, Fabienne Mougin
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in breast cancer patients. Sleep me
Externí odkaz:
https://doaj.org/article/5473dfa5db4749b08b82dda664fb277d
Autor:
Gaël Ennequin, Lidia Delrieu, Adrien Rossary, Quentin Jacquinot, Fabienne Mougin, David Thivel, Martine Duclos
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
Externí odkaz:
https://doaj.org/article/432daf38cf1c4f6e8807631522cb162a
Autor:
Quentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, Malika Bouhaddi, Pauline Roux, Bruno Degano, Marion Chatot, Elsa Curtit, Laura Mansi, Marie-Justine Paillard, Fernando Bazan, Loïc Chaigneau, Erion Dobi, Guillaume Meynard, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective sup
Externí odkaz:
https://doaj.org/article/b99f6aa41f744bdf96b74aa0e763ad8d
Autor:
Christelle d’Engremont, Julienne Grillot, Julie Raillat, Dewi Vernerey, Lucine Vuitton, Stéphane Koch, Célia Turco, Bruno Heyd, Guillaume Mouillet, Quentin Jacquinot, Christophe Borg, Angélique Vienot
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundSurgical resection with adjuvant chemotherapy is the only treatment that can provide long term survival in localized pancreatic ductal adenocarcinoma (LPDAC). Notwithstanding, recurrence occurs in the vast majority of patients and a better
Externí odkaz:
https://doaj.org/article/117dca53e2784cf18dd7bba41ec3924e
Autor:
Quentin Jacquinot, Nathalie Meneveau, Marion Chatot, Franck Bonnetain, Bruno Degano, Malika Bouhaddi, Gilles Dumoulin, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejec
Externí odkaz:
https://doaj.org/article/51125522a32e4989bcba30586fbc60c4
Autor:
Aude-Marie Foucaut, Quentin Jacquinot, Thomas Ginsbourger, Laura Turnaco, Romane Lamotte, Fabienne Mougin
Publikováno v:
Bulletin du Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f2209046ae971dd925d9a3c2443666
https://doi.org/10.1016/j.bulcan.2023.03.024
https://doi.org/10.1016/j.bulcan.2023.03.024
Publikováno v:
Movement & Sport Sciences - Science & Motricité. :39-44
Breast cancer, the most common in women, is a cancer of good prognosis. During this last decade, the improvement of cancer screening and treatment has significantly increased disease-free and overall survival. However, the chemotherapy, especially ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00700fc7e88158fddf9674b9d79fa2de
https://doi.org/10.1051/sm/2018016
https://doi.org/10.1051/sm/2018016
Autor:
Pierre Fumoleau, Jean-Yves Pierga, Sophie Paget-Bailly, Julie Henriques, Alain Lortholary, Quentin Jacquinot, Celine Faure Mercier, Iris Pauporté, Xavier Pivot, Jean-Marc Nabholtz, Gilles Romieu, Marc Espié
Publikováno v:
Breast (Edinburgh, Scotland). 41
Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT0038
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b0c0a311a1684d9d5154d6313460573
https://pubmed.ncbi.nlm.nih.gov/29913374
https://pubmed.ncbi.nlm.nih.gov/29913374
Autor:
Camille Corradini, Bruno Degano, Malika Bouhaddi, Fabienne Mougin, Quentin Jacquinot, Nathalie Meneveau
Publikováno v:
Science & Sports. 33:S19-S20
Introduction Un tiers des cancers du sein surexprime la proteine HER2 [1] . Les traitements radio-chimiotherapique et par trastuzumab s’accompagnent de douleurs, d’une fatigue, d’une diminution de la capacite aerobie alterant la qualite de vie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb958d24e8efa23e461328094c41f3c7
https://doi.org/10.1016/j.scispo.2018.03.023
https://doi.org/10.1016/j.scispo.2018.03.023